Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UQ84
UPID:
EXO1_HUMAN
Alternative names:
Exonuclease I
Alternative UPACC:
Q9UQ84; O60545; O75214; O75466; Q5T396; Q96IJ1; Q9UG38; Q9UNW0
Background:
Exonuclease 1, alternatively known as Exonuclease I, plays a pivotal role in DNA repair mechanisms, specifically in DNA mismatch repair (MMR). It exhibits a unique 5'->3' double-stranded DNA exonuclease activity and potentially a 3'->5' activity, targeting mismatch-containing DNA tracts. Furthermore, it acts on 5'-overhanging flap structures, crucial for the processing of Okazaki fragments during DNA replication. Its essential functions extend to somatic hypermutation (SHM) and class switch recombination (CSR) of immunoglobulin genes, highlighting its significance in immune response and meiosis.
Therapeutic significance:
Understanding the role of Exonuclease 1 could open doors to potential therapeutic strategies.